What is the success rate of stem cell therapy for Diabetes (Type 1 & 2)?
No pooled success rate applies across donor islets, stem-cell-derived islets, MSCs and different diabetes types. For an exact product, review severe-hypoglycaemia outcomes, HbA1c, insulin use, graft function, adverse events and follow-up with denominators and missing data.
What the evidence shows for Diabetes (Type 1 & 2)
FDA-approved Lantidra (donislecel-jujn) is an allogeneic pancreatic-islet cellular therapy made from deceased-donor pancreatic cells for a narrow group of adults with Type 1 diabetes and recurrent severe hypoglycaemia despite intensive management. It is infused into the hepatic portal vein and requires concomitant immunosuppression; it is not a general stem-cell cure for Type 1 or Type 2 diabetes. See the FDA Lantidra record and the NIDDK islet-transplant overview.
Am I a candidate? → · Diabetes (Type 1 & 2): full overview → · Diabetes (Type 1 & 2) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Diabetes (Type 1 & 2): cell-therapy evidence and registered trials
- How much does stem cell therapy for Diabetes (Type 1 & 2) cost? (2026)
- Diabetes (Type 1 & 2) stem cell therapy — your questions answered (2026)
- Diabetes (Type 1 & 2): cell-therapy evidence by therapy class
- MSC vs HSCT for Diabetes (Type 1 & 2): what the registries show